Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

632 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma.
Schmitz N, Kloess M, Reiser M, Berdel WE, Metzner B, Dorken B, Kneba M, Trumper L, Loeffler M, Pfreundschuh M, Glass B; German High-Grade Non Hodgkin's Lymphoma Study Group (DSHNHL). Schmitz N, et al. Among authors: loeffler m. Cancer. 2006 Jan 1;106(1):136-45. doi: 10.1002/cncr.21588. Cancer. 2006. PMID: 16331635 Free article. Clinical Trial.
Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma.
Glass B, Kloess M, Bentz M, Schlimok G, Berdel WE, Feller A, Trümper L, Loeffler M, Pfreundschuh M, Schmitz N; German High-Grade Non-Hodgkin Lymphoma Study Group. Glass B, et al. Among authors: loeffler m. Blood. 2006 Apr 15;107(8):3058-64. doi: 10.1182/blood-2005-04-1570. Epub 2005 Dec 29. Blood. 2006. PMID: 16384932 Free article. Clinical Trial.
A functional polymorphism in the NAD(P)H oxidase subunit CYBA is related to gene expression, enzyme activity, and outcome in non-Hodgkin lymphoma.
Hoffmann M, Schirmer MA, Tzvetkov MV, Kreuz M, Ziepert M, Wojnowski L, Kube D, Pfreundschuh M, Trümper L, Loeffler M, Brockmöller J; German Study Group for High-Grade Non-Hodgkin Lymphoma. Hoffmann M, et al. Among authors: loeffler m. Cancer Res. 2010 Mar 15;70(6):2328-38. doi: 10.1158/0008-5472.CAN-09-2388. Epub 2010 Mar 9. Cancer Res. 2010. PMID: 20215507
Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group.
Schmitz N, Trümper L, Ziepert M, Nickelsen M, Ho AD, Metzner B, Peter N, Loeffler M, Rosenwald A, Pfreundschuh M. Schmitz N, et al. Among authors: loeffler m. Blood. 2010 Nov 4;116(18):3418-25. doi: 10.1182/blood-2010-02-270785. Epub 2010 Jul 21. Blood. 2010. PMID: 20660290 Free article. Clinical Trial.
TP53 mutation and survival in aggressive B cell lymphoma.
Zenz T, Kreuz M, Fuge M, Klapper W, Horn H, Staiger AM, Winter D, Helfrich H, Huellein J, Hansmann ML, Stein H, Feller A, Möller P, Schmitz N, Trümper L, Loeffler M, Siebert R, Rosenwald A, Ott G, Pfreundschuh M, Stilgenbauer S; German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Zenz T, et al. Among authors: loeffler m. Int J Cancer. 2017 Oct 1;141(7):1381-1388. doi: 10.1002/ijc.30838. Epub 2017 Jun 26. Int J Cancer. 2017. PMID: 28614910 Clinical Trial.
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.
Poeschel V, Held G, Ziepert M, Witzens-Harig M, Holte H, Thurner L, Borchmann P, Viardot A, Soekler M, Keller U, Schmidt C, Truemper L, Mahlberg R, Marks R, Hoeffkes HG, Metzner B, Dierlamm J, Frickhofen N, Haenel M, Neubauer A, Kneba M, Merli F, Tucci A, de Nully Brown P, Federico M, Lengfelder E, di Rocco A, Trappe R, Rosenwald A, Berdel C, Maisenhoelder M, Shpilberg O, Amam J, Christofyllakis K, Hartmann F, Murawski N, Stilgenbauer S, Nickelsen M, Wulf G, Glass B, Schmitz N, Altmann B, Loeffler M, Pfreundschuh M; FLYER Trial Investigators; German Lymphoma Alliance. Poeschel V, et al. Among authors: loeffler m. Lancet. 2019 Dec 21;394(10216):2271-2281. doi: 10.1016/S0140-6736(19)33008-9. Lancet. 2019. PMID: 31868632 Clinical Trial.
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL.
Pfreundschuh M, Trümper L, Kloess M, Schmits R, Feller AC, Rudolph C, Reiser M, Hossfeld DK, Metzner B, Hasenclever D, Schmitz N, Glass B, Rübe C, Loeffler M; German High-Grade Non-Hodgkin's Lymphoma Study Group. Pfreundschuh M, et al. Among authors: loeffler m. Blood. 2004 Aug 1;104(3):626-33. doi: 10.1182/blood-2003-06-2094. Epub 2004 Feb 24. Blood. 2004. PMID: 14982884 Free article. Clinical Trial.
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.
Pfreundschuh M, Trümper L, Kloess M, Schmits R, Feller AC, Rübe C, Rudolph C, Reiser M, Hossfeld DK, Eimermacher H, Hasenclever D, Schmitz N, Loeffler M; German High-Grade Non-Hodgkin's Lymphoma Study Group. Pfreundschuh M, et al. Among authors: loeffler m. Blood. 2004 Aug 1;104(3):634-41. doi: 10.1182/blood-2003-06-2095. Epub 2004 Mar 11. Blood. 2004. PMID: 15016643 Free article. Clinical Trial.
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).
Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, Reiser M, Nickenig C, Clemens M, Peter N, Bokemeyer C, Eimermacher H, Ho A, Hoffmann M, Mertelsmann R, Trümper L, Balleisen L, Liersch R, Metzner B, Hartmann F, Glass B, Poeschel V, Schmitz N, Ruebe C, Feller AC, Loeffler M; German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Pfreundschuh M, et al. Among authors: loeffler m. Lancet Oncol. 2008 Feb;9(2):105-16. doi: 10.1016/S1470-2045(08)70002-0. Epub 2008 Jan 15. Lancet Oncol. 2008. PMID: 18226581 Clinical Trial.
CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).
Boehme V, Schmitz N, Zeynalova S, Loeffler M, Pfreundschuh M. Boehme V, et al. Among authors: loeffler m. Blood. 2009 Apr 23;113(17):3896-902. doi: 10.1182/blood-2008-10-182253. Epub 2009 Jan 14. Blood. 2009. PMID: 19144985 Free article. Clinical Trial.
632 results